ABL1 and cancer: Therefore, BCR-ABL inhibitors are not only historically significant for their pioneering role in targeted cancer therapy via well-characterized mechanisms, but are also pharmacologically versatile, making them unique tools for both precision oncology and the expanding field of drug repurposing and systems pharmacology.